MD MSc - Delcath Systems Chief Officer
| DCTH Stock | USD 13.44 0.25 1.90% |
Executive
MD MSc is Chief Officer of Delcath Systems
| Age | 57 |
| Address | 1633 Broadway, New York, NY, United States, 10019 |
| Phone | 212 489 2100 |
| Web | https://www.delcath.com |
Delcath Systems Management Efficiency
The company has return on total asset (ROA) of (0.1347) % which means that it has lost $0.1347 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.5859) %, meaning that it created substantial loss on money invested by shareholders. Delcath Systems' management efficiency ratios could be used to measure how well Delcath Systems manages its routine affairs as well as how well it operates its assets and liabilities. The current Return On Tangible Assets is estimated to decrease to -0.36. The current Return On Capital Employed is estimated to decrease to -0.18. As of now, Delcath Systems' Fixed Asset Turnover is increasing as compared to previous years. The Delcath Systems' current Asset Turnover is estimated to increase to 0.43, while Non Currrent Assets Other are projected to decrease to (0.94).Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Robert John | CVRx Inc | N/A | |
| Badri Amurthur | LivaNova PLC | N/A | |
| Stephanie Walsh | Orthofix Medical | N/A | |
| Gregory Firestone | Tela Bio | 66 | |
| Philip Kowalczyk | LivaNova PLC | N/A | |
| Roberto Donadello | Orthofix Medical | N/A | |
| Rachel Osbeck | Treace Medical Concepts | N/A | |
| Debbie Garner | Avita Medical | N/A | |
| Stephen JD | Sight Sciences | N/A | |
| Irene Thomas | Neuropace | 55 | |
| Dan Yarbrough | Orthofix Medical | N/A | |
| Jacqueline Keller | Clearpoint Neuro | N/A | |
| David JD | Pulmonx Corp | 64 | |
| Katie Bush | Avita Medical | N/A | |
| Amy Treadwell | Neuropace | N/A | |
| John Manders | SurModics | 43 | |
| Brenton Taylor | Sight Sciences | 44 | |
| Guy Guglielmino | Treace Medical Concepts | N/A | |
| Michael Leonard | Tela Bio | N/A | |
| Gerardo Hernandez | TransMedics Group | N/A | |
| Sean Scanlan | Treace Medical Concepts | 42 | |
Management Performance
| Return On Equity | -0.59 | ||||
| Return On Asset | -0.13 |
Delcath Systems Leadership Team
Elected by the shareholders, the Delcath Systems' board of directors comprises two types of representatives: Delcath Systems inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Delcath. The board's role is to monitor Delcath Systems' management team and ensure that shareholders' interests are well served. Delcath Systems' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Delcath Systems' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Robin Wagge, VP Associates | ||
| David Hoffman, Corporate Counsel | ||
| MD MSc, Chief Officer | ||
| Kevin Muir, VP Operations | ||
| Johnny MD, Senior Affairs | ||
| Sandra Pennell, Senior Officer | ||
| Vojislav MD, Chief Officer | ||
| MS MBA, CEO Director | ||
| John MS, Chief Officer | ||
| Sandra CPA, Senior Officer | ||
| David JD, Corporate Counsel | ||
| Michael MD, Senior Oncology | ||
| Martha Rook, Chief Officer | ||
| Anthony Dias, VP Fin |
Delcath Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Delcath Systems a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.59 | ||||
| Return On Asset | -0.13 | ||||
| Profit Margin | (0.71) % | ||||
| Operating Margin | 0.20 % | ||||
| Current Valuation | 388.39 M | ||||
| Shares Outstanding | 33.4 M | ||||
| Shares Owned By Insiders | 2.70 % | ||||
| Shares Owned By Institutions | 41.33 % | ||||
| Number Of Shares Shorted | 881.51 K | ||||
| Price To Earning | (0.12) X |
Currently Active Assets on Macroaxis
When determining whether Delcath Systems offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Delcath Systems' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Delcath Systems Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Delcath Systems Stock:Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Delcath Systems. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. For more detail on how to invest in Delcath Stock please use our How to Invest in Delcath Systems guide.You can also try the Balance Of Power module to check stock momentum by analyzing Balance Of Power indicator and other technical ratios.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Delcath Systems. If investors know Delcath will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Delcath Systems listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.93) | Revenue Per Share | Quarterly Revenue Growth 27.015 | Return On Assets | Return On Equity |
The market value of Delcath Systems is measured differently than its book value, which is the value of Delcath that is recorded on the company's balance sheet. Investors also form their own opinion of Delcath Systems' value that differs from its market value or its book value, called intrinsic value, which is Delcath Systems' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Delcath Systems' market value can be influenced by many factors that don't directly affect Delcath Systems' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Delcath Systems' value and its price as these two are different measures arrived at by different means. Investors typically determine if Delcath Systems is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Delcath Systems' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.